Body system: Respiratory SystemRegulation: 38 CFR § 4.97
Drug-induced pulmonary pneumonitis and fibrosis is interstitial lung disease caused by toxic exposure to certain medications (chemotherapy, amiodarone, nitrofurantoin, methotrexate, etc.). The VA rates this condition under the General Rating Formula for Interstitial Lung Disease (38 CFR § 4.97) from 10% to 100% based on pulmonary function testing: FVC (forced vital capacity), DLCO (diffusion capacity for carbon monoxide), maximum exercise capacity, and the presence of cor pulmonale, pulmonary hypertension, or required outpatient oxygen therapy.
Rating levels
- 100% — You qualify for 100% if pulmonary function testing shows FVC less than 50% predicted, OR DLCO (single-breath method) less than 40% predicted, OR maximum exercise capacity less than 15 ml/kg/min oxygen consumption with cardiorespiratory limitation, OR cor pulmonale (right-heart strain from chronic lung disease) or pulmonary hypertension is present, OR you require outpatient oxygen therapy. Any one of these findings is sufficient for the 100% rating.
- 60% — You qualify for 60% if pulmonary function testing shows FVC of 50% to 64% predicted, OR DLCO (single-breath method) of 40% to 55% predicted, OR maximum exercise capacity of 15 to 20 ml/kg/min oxygen consumption with cardiorespiratory limitation. Any one of these findings is sufficient.
- 30% — You qualify for 30% if pulmonary function testing shows FVC of 65% to 74% predicted, OR DLCO (single-breath method) of 56% to 65% predicted. Either finding is sufficient.
- 10% — You qualify for 10% if pulmonary function testing shows FVC of 75% to 80% predicted, OR DLCO (single-breath method) of 66% to 80% predicted. This represents mild impairment, either finding is sufficient.